PFM Health Sciences’s Cytokinetics CYTK Stock Holding History

PFM Health Sciences’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3M	Buy	+191,686	New	+$13.8M	1.4%	21
2024 Q4	–	Sell	-1,757,192	Closed	-$92.8M	–	91
2024 Q3	$92.8M	Hold	1,757,192	–	–	5.26%	3
2024 Q2	$95.2M	Hold	1,757,192	–	–	4.71%	2
2024 Q1	$123M	Hold	1,757,192	–	–	5.79%	2
2023 Q4	$147M	Sell	1,757,192 -642,353	-27%	-$23.3M	8.8%	2
2023 Q3	$70.7M	Hold	2,399,545	–	–	3.33%	4
2023 Q2	$78.3M	Hold	2,399,545	–	–	3.04%	4
2023 Q1	$84.4M	Hold	2,399,545	–	–	3.73%	4
2022 Q4	$110M	Sell	2,399,545 -65,471	-3%	-$2.82M	3.94%	2
2022 Q3	$119M	Hold	2,465,016	–	–	4.32%	1
2022 Q2	$96.8M	Hold	2,465,016	–	–	3.69%	2
2022 Q1	$90.7M	Hold	2,465,016	–	–	3.39%	6
2021 Q4	$112M	Sell	2,465,016 -694,685	-22%	-$26.8M	3.83%	5
2021 Q3	$113M	Buy	3,159,701 +1,472,689	+87%	+$43.4M	3.32%	5
2021 Q2	$33.4M	Buy	1,687,012 +150,639	+10%	+$3.54M	1.05%	37
2021 Q1	$35.7M	Buy	1,536,373 +565,222	+58%	+$12.1M	1.09%	33
2020 Q4	$20.2M	Buy	+971,151	New	+$17.7M	0.71%	54

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PFM Health Sciences's CYTK Position: Q2 2026 in Review

PFM Health Sciences opened a new position in Cytokinetics (CYTK) in Q2 2026: 191,686 shares worth $16.3M. The stake represents 1.4% of the portfolio and ranks #21 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in CYTK as recently as Q3 2024.

PFM Health Sciences first reported a position in CYTK in Q4 2020 and has held it in 17 quarters since. The position peaked at $147M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

PFM Health Sciences held 191,686 shares of Cytokinetics worth $16.3M as of Q2 2026.
Cytokinetics was a new PFM Health Sciences position in Q2 2026.
Cytokinetics made up 1.4% of PFM Health Sciences's portfolio in Q2 2026, its #21 holding.
PFM Health Sciences first reported a position in Cytokinetics in Q4 2020 and has held it in 17 quarters since.
PFM Health Sciences's Cytokinetics position peaked at $147M in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.